生物制药软件和分析公司Certara（CERT）周一盘后股价大涨5.25%，引发投资者关注。
这一显著涨幅主要受益于投行杰富瑞对该公司股票的看好。杰富瑞分析师在最新研究报告中将Certara的目标股价从12.50美元上调至14.50美元，上调幅度达16%。这一积极的目标价调整反映了分析师对Certara未来业务前景和市场表现的乐观预期。
Certara公司专注于为生物制药行业提供药物开发和监管审批相关的软件解决方案和分析服务。杰富瑞的目标价上调可能表明分析师看好该公司在生物制药科技领域的增长潜力。投资者对这一利好消息反应积极，推动了股价的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.